PlexBio
Taipei, Taiwan· Est.
Taiwanese IVD leader delivering high‑throughput multiplex diagnostics via its patented πCode platform.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwanese IVD leader delivering high‑throughput multiplex diagnostics via its patented πCode platform.
OncologyInfectious Diseases
Technology Platform
The patented Precision Image Code MicroDisc (πCode) enables high‑density multiplex detection through fluorescence imaging, integrated with the automated IntelliPlex™ workstation for sample‑to‑answer molecular diagnostics.
Opportunities
Expansion into U.S.
and European IVD markets and broadening the oncology assay portfolio could drive significant revenue growth.
Risk Factors
Regulatory approval timelines and competition from larger diagnostic manufacturers may limit market penetration.
Competitive Landscape
Key competitors include Roche cobas, Abbott m2000, and Thermo Fisher; PlexBio differentiates itself through its high‑plex πCode technology and integrated automation platform.